A 83-year-old female patient was admitted to our hospital due to hematological manifestation of juvenile granulocytes and macrocytic anemia. Bone marrow (BM) examination revealed erythroid dysplasia and cytoplasmic blasts, and hence the patient was diagnosed with myelodysplastic syndrome with ring sideroblasts and with single lineage dysplasia (MDS-RS-SLD). Erythrocyte transfusion was performed as a supportive therapy, and there was a gradual increase in the number of blood cells. Therefore, BM re-examination was performed and it was confirmed that the number of megakaryocytes increased, so the patient's condition was determined as myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T). Incidentally, gene mutation analysis showed CALR gene mutation. Thereafter, administration of hydroxycarbamide and anagrelide did not show adverse events and complications, and a good blood count control was obtained. Furthermore, it was also confirmed that an SF3B1 gene mutation is highly positive in MDS-RS. There was no report on CALR-mutant MDS/MPN in Japan, and it is a rare disease overseas.

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.915DOI Listing

Publication Analysis

Top Keywords

ring sideroblasts
12
gene mutation
12
sf3b1 gene
8
[concurrent calr
4
calr sf3b1
4
gene
4
gene mutations
4
mutations patient
4
patient myelodysplastic/myeloproliferative
4
myelodysplastic/myeloproliferative neoplasm
4

Similar Publications

X-linked sideroblastic anemia (XLSA) is a congenital anemia caused by mutations in ALAS2, a gene responsible for heme synthesis. Treatments are limited to pyridoxine supplements and blood transfusions, offering no definitive cure except for allogeneic hematopoietic stem cell transplantation, only accessible to a subset of patients. The absence of a suitable animal model has hindered the development of gene therapy research for this disease.

View Article and Find Full Text PDF

Besides transfusion therapy, ineffective erythropoiesis contributes to systemic iron overload in myelodysplastic syndromes with ring sideroblasts (MDS-RS) via erythroferrone-induced suppression of hepcidin synthesis in the liver, leading to increased intestinal iron absorption. The underlying pathophysiology of MDS-RS, characterized by disturbed heme synthesis and mitochondrial iron accumulation, is less well understood. Several lines of evidence indicate that the mitochondrial transporter ABCB7 is critically involved.

View Article and Find Full Text PDF

Myelodysplastic syndromes (MDS) are associated with anemia and the need for blood transfusions. In clinical trials, luspatercept reduced transfusion dependency among patients with lower-risk MDS. This United States (US) study describes real-world clinical outcomes pre- and post-luspatercept initiation among patients with MDS.

View Article and Find Full Text PDF

Gelatinous transformation of bone marrow associated with ring sideroblasts: A diagnostic pitfall.

Ann Diagn Pathol

December 2024

Department of Anatomical and Clinical Pathology, University of Texas Medical Branch, Galveston, TX, USA; Department of Pathology & Laboratory Medicine, Cleveland Clinic Florida, Weston, FL, USA. Electronic address:

Article Synopsis
  • Gelatinous bone marrow transformation (GBMT) is a rare medical condition involving the atrophy of fat cells and the buildup of a gelatinous substance in the bone marrow, leading to decreased blood cell production (hypoplastic hematopoiesis).
  • A study reviewed bone marrow specimens from patients with a BMI of <18.5, revealing that 30% of those evaluated had GBMT associated with ring sideroblasts, a specific type of abnormal red blood cell.
  • Notably, one patient’s ring sideroblasts were linked to copper deficiency, highlighting that GBMT may be misdiagnosed as myelodysplastic syndrome without further investigation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!